Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones.

Cell Res
Authors
Keywords
Abstract

Two recent papers identify KRAS activation as a mechanism of acquired resistance to EGFR blockade in colorectal cancer. In doing so, they suggest that resistance to single-agent EGFR blockade will be unavoidable because these alterations exist as latent subclones within the tumor even prior to the initiation of therapy.

Year of Publication
2013
Journal
Cell Res
Volume
23
Issue
1
Pages
13-4
Date Published
2013 Jan
ISSN
1748-7838
URL
DOI
10.1038/cr.2012.115
PubMed ID
22847744
PubMed Central ID
PMC3541651
Links
Grant list
T32 GM007753 / GM / NIGMS NIH HHS / United States